GlassScriptPhysician profile
Joseph P David
NPI 1851365936
$10,852.73
in general payments reported to CMS, 2019-2025
57 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $975 · 2021: $1,463 · 2022: $1,780 · 2023: $1,436 · 2024: $1,857 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,988 · Education: $29.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,987.80 |
| Education | $29.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,666.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,262.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,168.48 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $887.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $870.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $653.49 | 2019-2025 | |
| Glaxosmithkline, LLC. | $460.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.13 | 2020-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $274.44 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $257.71 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.15 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $215.65 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $191.22 | 2019-2024 | Xarelto |
| Melinta Therapeutics, LLC | $169.47 | 2019-2020 | |
| Kci USA, INC. | $139.59 | 2019-2023 | Promogran Prisma, Activ.A.C. |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.